Fig. 6: Silencing of cGAS-STING pathway and ICD-mediated immune response and its impact on tumor immunity. | Cell Death & Disease

Fig. 6: Silencing of cGAS-STING pathway and ICD-mediated immune response and its impact on tumor immunity.

From: Oncolytic peptide LTX-315 plus an anti-CTLA-4 antibody induces a synergistic anti-cancer immune response in residual tumors after radiofrequency ablation of hepatocellular carcinoma

Fig. 6

A Experimental workflow for silencing the cGAS-STING pathway and ICD in vivo studies. B, C Western blotting was used to confirm the knockout of cGAS and STING proteins in Hepa1-6 cells. D, E The proportion of mature dendritic cells (CD80+CD86+ DCs) was assessed after treatment with the anti-CD11c antibody. F, G Western blotting was applied to confirm the reduction of ICD-related molecules (ATP, CALR, HMGB1) after treatment with the anti-CD11c antibody. H, I Phosphorylation of TBK1 and IRF3 was reduced in tumors after silencing the cGAS-STING pathway. J, K Tumors were harvested and weight was assessed, showing an increase in tumor size after silencing the cGAS-STING pathway and ICD in all five groups. L–N Flow cytometry analysis was used to evaluate the levels of functional CD8+ T cells after silencing the cGAS-STING pathway and ICD in all five groups. n = 6 per group. Error bars represent standard deviation. Ns not statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001.

Back to article page